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Abstract 
Cytomegalovirus (CMV) is the most common congenital viral infection in the 
United States, causing more long-term developmental problems and early 
childhood deaths than Downs Syndrome, fetal alcohol syndrome, anencephaly, 
HIV/AIDS, haemophilus influenzae, and congenital rubella. CMV transmission to 
the fetus can result in numerous developmental and central nervous system 
morbidities. The direct annual cost of congenital CMV is estimated at 
approximately $1-$2 billion per year.  Despite the fact that almost all adults will 
contract CMV at some point, infection with the virus is preventable with simple 
hygiene techniques. While many national organizations have publicized 
recommendations regarding the impact and prevention of congenital CMV, the 
disease remains a persistent problem leading to the conclusion that the message is 
not being heard and acted upon.  Additionally, current recommendations may not 
be sufficient to address this issue. For example proactive screening for the 
identification of high risk pregnancies is not currently recommended.   
Based on a literature review of the natural history and pathogenesis of CMV, its 
prevailing disease burden, and the prevention of congenital CMV, the following 
programmatic recommendations seem feasible:  
 Develop programs for educating the affected population as well as 
ancillary populations 
 Develop more comprehensive campaigns designed to better promote 
congenital CMV-preventative behaviors 
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 Develop selective screening programs for the early identification of at-risk 
individuals or those infected with a high risk of fetal transmission 
 It is anticipated that an efficacious vaccine will not be developed for some time 
despite ongoing efforts.  As such, these recommendations represent more 
immediate preventative steps that can be adopted in lieu of an approved vaccine 
and can be used with continued vigilance once a vaccine has been made available 
to further strengthen ones protection against viral infection.   
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Introduction 
 
The objective of this paper is to present current information regarding 
cytomegalovirus (CMV), the impact of vertical transmission of CMV to the fetus 
during pregnancy, as well as the ways in which this transmission could be 
prevented.   
As part of the process in producing this paper and recommendations made therein, 
multiple peer-reviewed research articles and abstracts were reviewed and 
information derived from these sources is provided in the following pages.  These 
articles address the history and epidemiology of CMV, the prevalence of CMV 
infection in pregnant women, the occurrence of vertical CMV transmission, the 
health effects of CMV on the developing fetus, the types of preventative programs 
and recommendations currently in place, potential treatment modalities, the 
evidence of effectiveness of preventative recommendations, and the implications 
for future research.  
Recommendations regarding future preventative guidelines have been developed 
based on this literature review and are provided as a conclusion to this document. 
 
Background and Epidemiology 
 
Overview of Cytomegalovirus  
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Cytomegalovirus (CMV) is a double-stranded DNA virus of the herpesviridae 
family which includes herpes simplex virus types 1 and 2, varicella-zoster virus, β 
herpesviruses, cytomegalovirus, human herpesviruses 6 - 8, γ herpesviruses, and 
Epstein-Barr virus. CMV is transmitted during contact with individuals actively 
excreting virus via infected blood, saliva, urine, breast milk and other bodily 
secretions, organ transplantation, and transplacentally.  The incubation period for 
CMV infection is approximately 28-60 days.  Upon infection, the virus triggers an 
antibody response marked by increased Immunoglobulin M (IgM) and 
Immunoglobulin G (IgG) antibodies followed by residualIgG.  While 
mononucleosis-type symptoms are sometimes seen in primary infections, 
asymptomatic responses are usual.  After recovery from initial infection, CMV 
remains latent in host cells with recurrent infection possible after viral 
reactivation. 
1,2  
It is estimated that approximately 50-80% of all adults in the 
United States are infected with CMV by age 40.
3 
Differences between developing 
and western countries in prevailing age of infection have been noted.  For 
example, most infections are acquired in childhood in developing countries while 
initial infections are more common in adulthood in western countries. In the 
United States the prevalence of CMV increases along with the age of the 
population.  Various, genetically different, strains of CMV are known to exist and 
exhibit differences in virulence. 
4  
Though rare, re-infection with a new strain of 
the virus is possible resulting in CMV that is novel to the host’s immune system. 
1,2   
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Based on a 2007 study conducted by Colugnati et al to determine the incidence of 
CMV among populations, the incidence of infection among the United States 
population (ages 12-49) was 1.6 infections per 100 susceptible persons per year.  
When this statistic was combined with the basic reproductive rate, the authors 
found that the average infected person transmits CMV to nearly two susceptible 
persons in his/her lifetime.  Additionally, the authors noted that the incidence of 
infection was significantly higher among non-Hispanic blacks and Mexican 
Americans (than among non-Hispanic whites) and lower income households.
5,6 
 
 
CMV Risk Factors 
While almost all adults will be infected with CMV at some point in their lives, 
certain subgroups are more susceptible to the disease.  For example, those who 
are immunocompromised due to an active disease state (AIDS, autoimmune 
disease, etc.) or due to iatrogenic causes (receiving large doses of 
glucocorticosteroids, those undergoing chemotherapy or radiotherapy, etc.) are at 
greater risk.  Additionally, higher risk is associated with those having multiple sex 
partners and individuals who attend or work at daycare centers or otherwise have 
frequent close contact with children. 
4
  
 
Current Trends in CMV Detection and Treatment 
As with most viral infection, CMV can be identified in the human body by the 
presence of viral-specific antibodies termed Immunoglobulin G (IgG) and 
Immunoglobulin M (IgM).  The presence of IgM antibodies is generally a marker 
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of acute infection.  These antibodies are detectable for approximately 3-4 months, 
and may persist for up to a year or longer in certain situations.  IgG is produced 
later (though early on) in infection and CMV-specific IgG remains detectable 
throughout life after primary infection.  IgG is considered useful as a biological 
determinant of past or present CMV virus in infected individuals. 
5  In addition, 
determination of IgG avidity can help the clinician ascertain whether the infection 
is primary, recurrent, or re-infection.  Low avidity antibodies typically become 
apparent within one month of infection, gradually increasing in avidity as time 
goes on.  In general terms, low avidity antibodies are an indicator of primary/new 
infection whereas detection of high avidity antibodies indicates either reactivation 
or distant infection.
 7,8
    
 Historically, and in the adult patient with primary CMV infection, treatment is 
unnecessary because the virus has a minimal impact on daily life.  In fact, most 
adults, unless immunocompromised in some way, experience little to no direct 
reaction as a result of the infection. When symptomatic cases are identified and 
action is needed to prevent more serious consequences, antiviral medications are 
used for the treatment and management of CMV, with ganciclovir widely 
considered the drug of choice. 
5
 
Though researchers are actively pursuing effective and safe vaccines for the 
prevention of CMV, there currently is no licensed product available.  It is thought 
that an efficacious vaccine will eventually be available, but that the necessary 
developmental process will take several years.  With this thought in mind, non-
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pharmacologic interventions for the prevention of CMV/congenital CMV will be 
presented later in this paper. 
 
Congenital CMV 
 
Epidemiology of Congenital CMV 
While CMV infection in healthy adults is rarely symptomatic, it can be 
devastating to an unborn fetus if passed vertically from the infected mother.  
CMV is the most common congenital viral infection in the United States, causing 
more long-term developmental problems and early childhood deaths than Down 
Syndrome, fetal alcohol syndrome, anencephaly, HIV/AIDS, haemophilus 
influenzae, and congenital rubella. It is estimated that congenital CMV affects 
approximately 1 child in 150 births in the United States and approximately 1 in 
750 births result in a child that is born with or develops significant problems due 
to infection.
9,10 
CMV transmission to the fetus can result in significant morbidities 
including jaundice, thrombocytopenia, petechiae, hepatosplenomegaly, growth 
restriction, non-immune hydrops, hearing and/or vision loss, and long-term 
mental disability, among others.
1,10
  Many developmental deficiencies have been 
thought to be attributable to the viral affect on the placenta itself resulting in 
placental insufficiency as opposed to direct fetal infection.
 11 
Approximately 30-
50% of women of childbearing age in the United States are susceptible to primary 
CMV infection and between 1-4% of uninfected women will be infected during 
pregnancy.  Of the 1-4% of women who experience primary infection during 
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pregnancy, approximately 33% transmit CMV to their developing fetus.
9  
Vertical 
transmission is not specific to primary infection.  A study conducted by Kenneson 
and Cannon of reported results of systematic fetal screening for CMV found that 
while the transmission rate for women who experienced primary infection was 
approximately 32%, a transmission rate of 1.4% was also noted for mothers with 
recurrent infection during pregnancy.
9
  These findings seem to indicate that, while 
somewhat rare, vertical transmission stemming from recurrent maternal infection 
could also lead to significant morbidity for the unborn fetus. 
 
Pathophysiology and Vertical Transmission of CMV 
The vertical transmission of CMV to the fetus or placental insufficiency due to 
maternal infection is the most common intrauterine infection associated with 
congenital defect and is known to be based upon the uterine-placental interface.  
During the early stages of pregnancy, in anticipation of fetal development, the 
placenta begins to form a bridge to facilitate fetal support. The result is often 
referred to as the uterine-placental interface which allows for the more rapid 
movement of nutrient-rich maternal blood necessary for proper fetal development 
and also forms the foundation for the early development of fetal passive immunity 
through the transportation of maternal antibodies.
 12
 Ironically, this same interface 
along with the umbilical vein allows cells infected with CMV to enter fetal 
circulation. In addition, CMV-infected cells can also be shed into amniotic cells 
and fluid via the placenta and then ingested by the fetus allowing for infection of 
the developing fetus. 
13,14 
  In contrast to other commonly transmitted maternal 
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disease, CMV viral shedding is measured in months or years, making it possible 
for infection to be transmitted to the fetus for some time after maternal 
acquisition.  Transmission of the virus can occur at any gestational stage and 
women with primary infection during later stages may have a higher risk of fetal 
infection.
15
 However, it is speculated that infection during late gestation results in 
less severe fetal symptoms due to the timing of infection relative to fetal neuronal 
development.
16
 In addition, vertical transmission has been shown to occur due to 
reactivation of latent infection or maternal re-infection with a viral strain different 
from primary infection in cases of known positive serology. 
17  
However, pre-
existing maternal antibody
 
protection seems to positively affect fetal outcomes 
and reduce damage to the fetus.  Fowler et al conducted a study of 197 children 
with congenital CMV infection in which maternal infection was either primary or 
recurrent.  Their findings indicated that antibodies to CMV due to existing latent 
infection extends at least some protection to the fetus and lessens severity of 
sequelae of the virus.
18
 
Vertical transmission of CMV infection is well documented, though we are still 
learning about how it affects fetal development and many of the recorded fetal 
morbidities could be the result of the virus on the development and sustainment of 
the placenta itself.
11 Infection of placental cells in the early stages of pregnancy 
could result in improper implantation of the placenta contributing to spontaneous 
abortion.  Placental effects later in gestation could result in the restriction of fetal 
growth and development.  Furthermore, many of the poor mental outcomes of 
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CMV-infected fetuses may be attributable to fetal hypoxia resulting from this 
placental pathology.  
 
Psychosocial and Financial Impacts of Congenital CMV 
While the psychosocial impact of congenital CMV cannot be quantified, it seems 
clear that this disease has a significant impact on the families of those it affects.  
Proof of this are the many published stories submitted by the parents of CMV-
infected children which are available through organizations like The CMV Action 
Network and other groups like the Parent to Parent CMV support group sponsored 
by CMVKids.  These first-hand accounts provide a glimpse into the pain and 
suffering these children and their families endure as well as the frustration of 
feeling uninformed regarding the existence and risk factors of CMV that often 
accompanies the pain.   
In terms of the financial impact, the direct annual cost of congenital CMV is 
estimated at approximately $1-$2 billion per year.
19 
 Additionally, given an 
effective preventative measure for congenital CMV, some studies have estimated 
a $50,000 per quality adjusted life-year savings.
20
  Outside of the United States, 
the financial burden brought about by this disease is just as problematic.  For 
example, Seale et al reported that the cost estimate of 104 congenital CMV single 
admissions was approximate $294,736 in their study of hospitalization trends for 
CMV-infected infants and children in Australia.
21
 Though these estimates were 
based upon general costs adjusted for relative complexity of patient disease, they 
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seem to support the idea that congenital CMV infection is a significant drain of 
public health resources.  
 
Current Congenital CMV Avoidance Recommendations and Screening 
Many organizations have documented recommendations for the prevention of 
congenital CMV.  For example, the CDC recommends that pregnant women 
avoid contact with the virus found in urine and saliva of young children by 
following these guidelines
22
: 
 Wash your hands often with soap and water for 15-20 seconds, especially 
after  
o changing diapers 
o feeding a young child 
o wiping a young child’s nose or drool 
o handling children’s toys 
 Do not share food, drinks, or eating utensils used by young children  
 Do not put a child’s pacifier in your mouth 
 Do not share a toothbrush with a young child 
 Avoid contact with saliva when kissing a child 
 Clean toys, countertops, and other surfaces that come into contact with 
children’s urine or saliva 
The American Congress of Obstetricians and Gynecologists (ACOG) promotes 
similar steps recommending frequent hand washing, especially after contact with 
a child who is in day care.
23 
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Baylor College of Medicine, via their National Congenital CMV Registry has 
developed a guide for distribution entitled ‘What Everyone Should Know About 
CMV’.  In this guide, the CDC steps above are advocated for and reinforced.24   
Clearly, these guidelines focus on limiting exposure to CMV via interactions with 
young children which is a known risk factor for the acquisition of CMV. 
Serologic screening for CMV in pregnant women is not currently recommended 
in the absence of clinical presentation in the mother or suspicious ultrasound 
findings in the fetus.  While CMV screenings are increasingly being performed in 
some areas with the hope of proactively identifying infection, the difficulty in 
determining fetal prognosis and the lack of proven treatment induces a sense of 
hesitation to issue clear guidelines among the various organizations that are 
known to exert influence among practitioners.   
 
Problems with Recommendations and Reasons for Change 
Preventative behavior, as recommended by the CDC and ACOG, revolve around 
common safe hygiene practices which are relatively simple and easy to adhere to. 
22,23  
However, although these recommendation are available to the public via 
various resources and practitioners are encouraged to provide counseling to 
expectant mothers regarding infection control, it is clear that this message is either 
not being heard or is misunderstood.  For example, Jeon et al reported that of 643 
women surveyed at seven pediatric outpatient facilities located in large US cities, 
only 22% reported any knowledge of congenital CMV.  Additionally, knowledge 
of CMV ranked last among other birth defects and childhood illnesses included in 
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the survey.  Further, among the 142 women who reported some knowledge of 
congenital CMV, there was alarming number who recorded inaccurate 
information regarding the disease as part of their survey response.  While the 
message was clearly not getting out, the saving grace was that of those who 
reported some knowledge of congenital CMV, 78% correctly indicated that 
pregnant women could transmit the disease to her developing fetus and 57% 
correctly reported that this transmission could possibly be avoiding by simple 
hand washing techniques.
25
  
One possible conclusion that can be drawn from the study above regarding the 
inadequacies of the education and information received by expectant mothers 
regarding congenital CMV is that those in the best position to educate them are 
unaware or misinformed as well. This conclusion is supported by a survey 
conducted by ACOG among members of its Collaborative Ambulatory Research 
Network (CARN) which is a nationally representative group of practicing 
Obstetricians and Gynecologists.  This study showed that only 44% of caregivers 
surveyed provided any form of counseling to their patients regarding CMV 
preventative measures.  Additionally, while approximately 90% of those surveyed 
reported knowing that hand washing reduces risk of CMV infection, a smaller 
proportion (57%) were aware that sharing utensils with young children and  
avoiding children’s salvia (55%) were effective countermeasures as well.26  These 
statistics seem to support the need for the promotion of simple, non invasive, 
strategies for the prevention of CMV acquisition and transmission – especially 
among high risk populations (e.g. those exposed to pre-school aged children).  In 
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addition, it is quite possible that although many people might be exposed to the 
concepts of good hygiene and the positive effects they may have in terms of viral 
avoidance, this behavior is not being put into practice.  Past research has shown 
that knowledge is necessary, but not sufficient to foster behavior change. This 
phenomenon is not unique to health care and some guidance can be drawn from 
the business literature. For example, it is similar to the concept known as the ‘The 
Knowing-Doing Gap’ referred to in the implementation of innovations  in 
business settings.  The ‘Knowing-Doing Gap’ points to complexity and 
reinforcement as prime considerations when disseminating information with the 
expectation of action.
27
 With this in mind, any interventions designed to elicit 
better hygiene among the targeted population must maintain a simple message 
that is easily understood and maintained by the audience and reinforcement 
techniques should be included to maximize adherence to the expected behavior 
change. These range from proven public health techniques, to more formal 
behavior modification techniques, such as social marketing, which have proven to 
be effective in public health and medical care. 
As noted in the previous section, no current recommendations for CMV screening 
in pregnant women exist.  CMV status, positive or negative, is a prime indicator 
of the potential for vertical transmission; however, status is often determined by 
the simple presence or absence of CMV-specific antibodies and, while helpful, 
this does not provide a timeline for infection. Though the presence of CMV 
antibodies is a good indicator of CMV infection in the maternal host, it can be 
misinterpreted in the presence of re infection or viral recurrence. On the other 
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hand, antibody avidity has been shown to be reliable in identifying primary 
infection in pregnant women.
28 
 The problems with utilizing simple CMV-specific 
antibody presence alone as a marker for primary CMV infection in the maternal 
host and the value of confirmatory antibody avidity can also be seen in the study 
presented by Cavlek et al which lends credence to the use of CMV-specific 
antibody avidity as a marker for new onset CMV infection . 
29
   
 
Recommendations and Future Strategies 
 
Based on the available literature, it seems clear that congenital CMV is a disease 
that can be prevented in many cases.  While pharmaceutical or vaccine options 
remain somewhat unproven, preventative measures are available that could 
provide considerable protection to the developing fetus at relatively low cost.  
Given the available data regarding the prevention of congenital CMV, its natural 
history and pathogenesis, and prevailing disease burden, the following 
programmatic recommendations seem feasible: 
 Develop programs for educating the affected population as well as 
ancillary populations 
 Develop more comprehensive campaigns designed to better promote 
CMV-preventative behaviors 
 Develop selective screening programs for the early identification of at-risk 
individuals or those infected with a high risk of fetal transmission 
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These recommendations represent more immediate preventative steps that can be 
adopted in lieu of an approved vaccine and can be used with continued vigilance 
once a vaccine has been made available to further strengthen ones protection 
against viral infection.  Each of these recommendations are discussed in greater 
detail below 
 
Developing Education Programs 
As is commonly said, ‘Knowledge is Power’.  As discussed previously, the Jeon 
et al study showed somewhat poor knowledge of congenital CMV among a 
relatively representative sample of women of child-bearing potential.
25
  Equally 
disturbing is the seeming lack of knowledge among caregivers, as noted  in the 
ACOG study, who historically serve as the primary educators of the targeted 
population.
 26 
 CMV is a disease without much fanfare and few consequences for 
most affected populations – thus CMV prevention is often an afterthought if 
considered at all.  Without prior knowledge of this disease, many individuals will 
unknowingly put their developing fetuses at risk.  This is especially true for more 
at risk populations such as those who are serologically CMV negative but who 
have frequent contact with young children or bodily secretions.   
Developing educational programs is a relatively inexpensive and non invasive 
means of informing the public of the risk factors involved in congenital CMV 
infections and the means in which this infection can be transferred to the 
developing fetus.  These educational programs can be marketed to all women of 
child-bearing potential regardless of known serostatus, to applicable healthcare 
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providers, as well as to ancillary locations such as daycares and churches.  Key to 
this effort will be the recruitment and development of collaborative partnerships 
with national stakeholders such as The Centers for Disease Control and 
Prevention and The American Congress of Obstetricians and Gynecologists as 
well as private and non profit organizations such as The Congenital CMV 
Foundation and The CMV Action network.  Many of these organizations have 
similar, existing, programs that can benefit from group synergy – allowing them 
to collectively affect change among more varied populations.  Additionally, these 
organizations will often have well-established funding mechanisms and sources 
that can be brought to bear more effectively for common ground goals. 
 
Developing Campaigns for the Promotion of Preventative Behavior 
As noted in the previous discussion of the proposed educational campaign, 
informing those potentially affected by congenital CMV as well as those 
occupying positions that can be leveraged to provide education is a relatively 
inexpensive means of inspiring behavioral change.  Michael Cannon and 
Katherine Davis detailed the merits of this intervention in their article entitled 
‘Washing our hands of the congenital cytomegalovirus disease epidemic’. In this 
article, the authors acknowledge that data regarding the effectiveness is limited, 
but also describe congenital CMV as the greatest opportunity for improved 
outcomes among children among all other causes of birth defects and 
developmental disabilities.  The authors base their argument regarding the 
effectiveness of the intervention by focusing on the ineffectiveness of methods to 
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promote it.  In fact, they clearly outline the non existent arguments against both 
the effectiveness and efficacy of hand washing intervention by citing the fact that 
hands are indisputably important vehicles in the transmission of disease and that 
the effectiveness of good hygiene techniques have been proven time and again. 
Further, they stress that individual women have a right to be informed of the 
potential effectiveness of these methods against the transmission of CMV and that 
medical professionals have an ethical obligation to inform all women, regardless 
of serostatus (there is a chance of re infection even with positive serostatus) of 
this opportunity just as they do in the case of safe sexual practices in the 
prevention of HIV transmission.
30
  
Evidence of successful hand washing campaigns is widely available.  For 
example, in a study of the effects of washing hands with soap on the development 
of diarrheal diseases, Curtis and Cairncross found up to a 44% risk reduction for 
diarrhea, a 48% risk reduction in severe intestinal infections and a 59% risk 
reduction in shigellosis when good hand washing practices were adhered to. 
31
  
While hand washing is perhaps the most productive target among CMV-related 
prevention measures, other measures as noted in the CDC congenital CMV 
infection prevention guidelines share the same underlying infection control 
themes.  Any activity in which infected bodily secretion could presumably be 
transmitted from the initial host to a new host should be avoided or counteracted.  
For example, the sharing of food/drinks, oral hygiene instruments, kissing, etc. 
with young children while pregnant should be avoided.   
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In light of previous sections in which the insufficiency of current attempts to 
inform both the general public and health care providers have been discussed, I 
believe it is important to touch upon the concept of social marketing and its 
potential application in future congenital CMV prevention interventions.  Social 
Marketing uses marketing principles which can be applied in situations where 
changing human behavior is the intended outcome.  For any public health 
application, it is important to determine if the intervention exhibits specific 
characteristics including relative change over what currently exists, compatibility 
with current norms, and non complexity, among others.
32
 The use of social 
marketing techniques as they pertain to our proposed education-based CMV-
prevention strategies would help to remove perceived barriers to behavior changes 
among our targeted audience as well as allow us to set realistic expectations for 
the initial success of the proposed program.   
 
Developing Selective Screening Programs 
Probably the most controversial component of this proposed congenital CMV 
infection prevention strategy is the implementation and use of screening 
programs.  It has been widely argued that the implementation of such programs as 
they pertain to congenital CMV would suffer from marginal testing 
specificity/sensitivity, economic constraints, and ethical considerations.  One, 
classic, example of this is Schlesinger’s paper entitled ‘Routine Screening for 
CMV in Pregnancy: Opening the Pandora Box?’ in which the author applies the 
Principles of Early Disease Detection as (championed by Wilson and Jungner).  In 
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doing so, the author admits that the severity and prevalence of congenital CMV 
seemed to meet these principles but that test discrimination, diagnostic timing, 
possible intervention, and cost-effectiveness preclude formal congenital CMV 
screening programs.
33 
While the author calls into question the sensitivity, 
specificity and general reliability of single antibody-based CMV screening 
programs,  he acknowledges the potential effectiveness of full panel antibody 
screening including avidity testing.  With this in mind, I would propose a 
screening program that incorporates all of the current primary antibody-specific 
assessments in order to not only identify the serologic status of the individual but 
also to offer some measure of viral aging to differentiate residual maternal CMV 
infection from primary, potentially problem causing, infection.
 
The combination 
of these tests should allow the care giver to establish one of three baseline 
serology statuses and courses of follow-up for the patient:  
 Uninfected/High Risk of New Maternal Infection: The patient is at high 
risk of primary infection, the course of action will be dependent upon the 
results of a serial screening process in which the patient will be monitored 
every 3 months for new infection as determined by the sudden detection of 
CMV-specific antibodies.  
 Infected/High Risk of New Maternal Infection: The subject is positive for 
CMV antibodies and there is possible risk of infection for the developing 
fetus(s).  In this situation, CMV antibody Avidity testing will be 
performed to determine the relative age of the infection.  The age of the 
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infection will serve as an indicator of potential risk to the fetus(s) which 
will be used to drive additional intervention    
 Residual Infection: In this scenario,  primary maternal infection is remote 
and the patient will receive continued hygiene education to restrict the 
possibility of re-infection 
Initial screening is conducted to determine the potential for maternal-fetal CMV 
transmission. Emphasis is placed upon primary maternal infection as this has been 
shown to result in a far greater number of symptomatic fetal infections.
18 
By 
establishing a baseline status early in the first trimester of gestation, new infection 
can be more readily identified in those of highest risk for fetal transmission and 
appropriate steps can be taken to possibly control infection.  Additional details 
regarding this proposed CMV screening program can be found in Appendix I. 
 
Conclusions 
 
Congenital CMV is a proven cause of viral-related developmental handicaps and 
other morbidities among children throughout the world.  As such, it is also known 
to create substantial burden on public health systems.  While further research is 
needed regarding the cost of the suggested screening program and the potential 
for antiviral intervention, I think it is important to consider this non invasive 
means of proactively identifying those at highest risk of new maternal infection.  
Implementing campaigns to inform both those at risk of transmitting this disease 
to their unborn children as well as those in positions to further educate them 
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coupled with well planned and implemented screening algorithms should 
significantly decrease the incidence of this disease and its associated emotional 
and financial costs.   
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Appendix I: Additional Information Regarding Viral antibodies and 
Suggested Screening Program 
 
As with most viral infections, CMV can be identified in the human body by the 
presence of viral-specific antibodies termed Immunoglobulin G (IgG) and 
Immunoglobulin M (IgM).  Upon infection, the virus triggers an antibody 
response marked by increased Immunoglobulin M (IgM) antibodies followed by 
residual Immunoglobulin G (IgG). As you can see in Figure I below, IgM 
antibodies become detectable early in the primary infection process and may 
continue to circulate long after primary infection.  Low avidity IgG typically 
becomes apparent within one month of infection, gradually increasing in avidity 
as time goes on.
7,8 
Figure I: Relative Levels of IgM and IgG Antibodies and IgG Avidity during CMV infection 
 
Our proposal includes the active screening of all women as they present for their 
initial first trimester obstetric/gynecology appointment.  This testing would 
include both IgM and IgG serology assessments as well as IgG avidity testing.   
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The combination of these tests should allow the care giver to establish one of 
three baseline serology statuses and courses of follow-up for the patient:  
 IgM-/IgG- (Uninfected/High Risk of New Maternal Infection): The 
subject is serologically negative for CMV antibodies.  The absence of both 
IgM and IgG indicates the patient is at high risk of primary infection, the 
course of action will be dependent upon the results of a serial screening 
process in which the patient will be monitored every 3 months for 
seroconversion as determined by the sudden detection of either IgM or 
IgG antibodies.  If the patient seroconverts at anytime during pregnancy, 
the patient will be counseled regarding potential fetal infection and 
pharmaceutical treatment may be recommended as prophylaxis.  Fetal 
infection will be monitored via clinical methods (e.g. ultrasound findings, 
MRI, amniocentesis, etc.).   
 IgM+/IgG+ (Infected/High Risk of New Maternal Infection): The subject 
is serologically positive for CMV antibodies and there is possible risk of 
infection for the developing fetus(s).  In this situation, IgG Avidity testing 
will be performed to determine the relative age of the infection.  The age 
of the infection will serve as an indicator of potential risk to the fetus(s) as 
low avidity is associated with new/primary infection.  If the testing reveals 
low avidity, the patient will be counseled regarding potential fetal 
infection and pharmaceutical treatment may be recommended as 
prophylaxis.  Fetal infection will be monitored via clinical methods (e.g. 
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ultrasound findings, MRI, amniocentesis, etc.).  IgG Avidity revealing 
residual infection will result in no further intervention. 
 IgG+/IgM (Residual Infection )-: In this scenario,  primary maternal 
infection is remote and the patient will receive continued hygiene 
education to restrict the possibility of re-infection 
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Figure II: Suggested Congenital CMV Screening Algorithm 
 
Initial screening is conducted to determine the potential of maternal-fetal CMV 
transmission. Emphasis is placed upon primary maternal infection as this has been 
shown to result in a far greater number of symptomatic fetal infections.
18
 
 These guidelines allow the caregiver to assign relative risk to individuals based 
upon IgG status and avidity aging.  This, combined with known ancillary risk 
factors will drive decisions for further intervention.  By establishing a baseline 
status early in the first trimester of gestation, seroconversion can be more readily 
identified in those of highest risk for fetal transmission and appropriate steps can 
be taken to possibly control infection.  With that said, although pharmacological 
intervention for congenital CMV is yet to be clinically proven, and further studies 
are required to establish true efficacy, I feel the use of treatment modalities that 
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are found to be effective for CMV in other infection scenarios should be applied 
in the event of positive confirmatory amniocentesis or hallmark imaging findings.   
Of note, it is important for the caregiver to understand the vital contribution of 
proper counseling for those who are identified as having passed this disease onto 
their children.  The purpose of proper counseling is to inform the patient of her 
options with regard to congenital and/or postpartum care.  As described by 
Revello and Gerna, the role of the care giver is to provide unbiased and 
informative counseling and impart relative knowledge to the patient.
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  In 
addition, it is imperative that caregivers remain cognizant of the impact of this 
screening program as well as the possibility of misuse and misinterpretation of the 
testing by some physicians which may incite unneeded anxiety among parents.  
Again, careful planning regarding the dissemination of the screening results and 
direct counseling will help to alleviate some of this anxiety.   
 
